Aptevo Therapeutics(DE:AP82)
€65,970.000.00 (0.00%)
DE:AP82
Aptevo Therapeutics financials statements
€65,970.00
At close:0.00 (0.00%)
Aptevo Therapeutics (AP82) Ratios
0 Followers
Aptevo Therapeutics Ratios
DE:AP82's free cash flow for Q2 2026 was $-5.45M. For the 2026 fiscal year, DE:AP82's free cash flow was increased by $0.00 and operating cash flow was $-5.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 |
| Quick Ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 |
| Cash Ratio | 3.57 | 1.40 | 2.34 | 2.60 | 1.30 |
| Solvency Ratio | -2.62 | -2.19 | -1.33 | 0.55 | -0.49 |
| Operating Cash Flow Ratio | -4.23 | -3.83 | -1.62 | -2.41 | -0.62 |
| Short-Term Operating Cash Flow Coverage | -29.55 | 0.00 | 0.00 | -10.51 | -1.86 |
| Net Current Asset Value | $ 13.27M | $ -177.00K | $ 6.45M | $ 11.21M | $ -2.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.30 | 0.22 | 0.28 | 0.30 |
| Debt-to-Equity Ratio | 0.27 | 0.97 | 0.44 | 0.53 | 13.75 |
| Debt-to-Capital Ratio | 0.21 | 0.49 | 0.31 | 0.35 | 0.93 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.75 |
| Financial Leverage Ratio | 1.56 | 3.28 | 2.03 | 1.90 | 46.55 |
| Debt Service Coverage Ratio | -29.71 | 0.00 | 0.00 | -13.87 | -1.74 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 16.59 | 0.00 | 0.00 | 0.17 | 0.24 |
| Interest Debt Per Share | 1467.19 | 6034.83 | 258533.84 | 1095673.50 | 2089680.62 |
| Net Debt to EBITDA | 0.66 | 0.17 | 0.41 | 0.47 | 1.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -919.75% | -174.10% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -890.82% | -164.79% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -919.75% | -174.10% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 225.24% | -239.25% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 257.77% | -231.51% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 225.24% | -239.25% |
| Net Income Per EBT | 100.00% | 100.00% | 93.36% | 114.44% | 96.77% |
| EBT Per EBIT | 98.69% | 98.08% | 64.58% | -24.49% | 137.42% |
| Return on Assets (ROA) | -95.49% | -154.77% | -70.09% | 23.46% | -50.28% |
| Return on Equity (ROE) | -149.40% | -507.47% | -142.47% | 44.66% | -2340.21% |
| Return on Capital Employed (ROCE) | -124.44% | -262.17% | -163.91% | -112.28% | -97.97% |
| Return on Invested Capital (ROIC) | -119.55% | -262.17% | -163.91% | -104.12% | -63.86% |
| Return on Tangible Assets | -95.49% | -154.77% | -70.09% | 23.46% | -50.28% |
| Earnings Yield | -87279.19% | -2027.47% | -786.24% | 67.84% | -77.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 1.25 | 3.35 |
| Payables Turnover | 0.27 | 0.12 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.46 | 3.10 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.09 | 0.22 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.17 | 0.49 |
| Cash Conversion Cycle | -1333.77 | -3165.75 | 0.00 | 293.03 | 108.80 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 293.03 | 108.80 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1333.77 | 3165.75 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 293.03 | 108.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8111.57 | -31008.52 | -561905.13 | -2415652.68 | -2710271.38 |
| Free Cash Flow Per Share | -8111.57 | -31008.52 | -561905.13 | -2418985.09 | -2799409.41 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -724.90 | -30.41 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -724.90 | -30.41 |
| Operating Cash Flow Coverage Ratio | -5.53 | -5.14 | -2.17 | -2.20 | -1.30 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -6.75 | -1.76 |
| Free Cash Flow Yield | -86018.76% | -1998.49% | -529.70% | -177.91% | -60.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.11 | -0.05 | -0.13 | 1.47 | -1.30 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 3.80 | 3.00 |
| Price-to-Book (P/B) Ratio | 0.00 | 0.25 | 0.18 | 0.66 | 30.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.00 | -0.05 | -0.19 | -0.56 | -1.65 |
| Price-to-Operating Cash Flow Ratio | -0.00 | -0.05 | -0.19 | -0.56 | -1.70 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | -0.01 | 0.04 |
| Enterprise Value Multiple | 0.66 | 0.08 | 0.27 | -0.28 | -1.80 |
| Enterprise Value | -16.94M | -2.00M | -7.62M | 7.67M | 36.42M |
| EV to EBITDA | 0.66 | 0.08 | 0.27 | -0.28 | -1.80 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 2.46 | 2.96 |
| EV to Free Cash Flow | 0.66 | 0.08 | 0.65 | -0.36 | -1.63 |
| EV to Operating Cash Flow | 0.66 | 0.08 | 0.65 | -0.36 | -1.68 |
| Tangible Book Value Per Share | 5509.03 | 6199.10 | 585425.63 | 2065404.87 | 152022.23 |
| Shareholders’ Equity Per Share | 5509.03 | 6199.10 | 585425.63 | 2065404.87 | 152022.23 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 357831.91 | 1536724.75 |
| Net Income Per Share | -8230.43 | -31458.30 | -834043.50 | 922388.17 | -3557645.31 |
| Tax Burden | 1.00 | 1.00 | 0.93 | 1.14 | 0.97 |
| Interest Burden | 1.00 | 1.00 | 0.65 | -0.24 | 1.37 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 5.74 | 1.55 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 4.46 | 1.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.58 | 0.13 |
| Income Quality | 0.99 | 0.99 | 0.67 | -2.62 | 0.76 |
Currency in USD
